Expand SLXN Menu
SLXN MENU

SLXN Latest Press Releases

-- August 14, 2026 --

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 8:45 AM

-- August 11, 2026 --

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering Globe Newswire 8:01 PM

-- August 4, 2026 --

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers Globe Newswire 9:15 AM

-- July 29, 2026 --

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center Globe Newswire 7:00 AM

-- June 23, 2026 --

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Globe Newswire 8:40 AM

-- June 16, 2026 --

Silexion Therapeutics to Attend BIO International Convention 2026 Globe Newswire 4:30 PM

-- May 26, 2026 --

Silexion Therapeutics Announces 1-for-10 Reverse Share Split Globe Newswire 8:31 AM

-- May 18, 2026 --

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 8:30 AM

-- May 15, 2026 --

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds Globe Newswire 8:27 AM

-- May 14, 2026 --

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer Globe Newswire 9:27 AM

-- May 13, 2026 --

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center Globe Newswire 8:00 AM

-- April 28, 2026 --

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer Globe Newswire 8:45 AM
Market Data Delayed 15 Minutes